Formulation and Evaluation of Nasal in situ Gel of Eletriptan Hydrobromide

Abstract

Aims: The nasal route has been found to be useful in targeting drugs to the central nervous system. As a target
tissue for medication delivery, nasal mucosa has many advantages. Drug administration through the nose is related
with systemic features a number of advantageous characteristics, including avoiding first-pass effects and having
a sizable amount of surface area accessible for absorption. Materials and Methods: A new dosage form for nasal
drug delivery, environment-sensitive gel has recently been used. In contrast to liquid nasal formulations, nasal
in situ gels are injected into the nasal cavity as low-viscosity solutions. When the polymer comes into contact with
the nasal mucosa, it changes conformation and forms a gel, which not only extends the time the drug is in contact
with the absorptive sites in the nasal cavity but also allows the drug to be released gradually and continuously.
Results and Discussion: This study set out to create and perfect a cold method-based nasal in situ gel formulation
for Eletriptan Hydro bromide. Thermosensitive polymer was used to prepare nasal in situ gels. Study of Solgel
transition temperature (Tsol-gel), rheological properties, in vitro release, and in vivo study was performed.
Conclusion: Cumulative drug release from thesenasal in situ gel containing Eletriptan Hydro bromide was within
the range of 42.92–86.12%. The cumulative drug release using nasal mucosa of goat was 70.44%. Th e enhanced
nasal residence time, improved bioavailability, increased brain uptake of parent drug and decreased exposure of
metabolites suggested that the in situ gel could be an effective intranasal formulation of Eletriptan Hydro bromide.